share_log

Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $52

Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $52

坎託·菲茨傑拉德維持對Celldex Therapeutics的增持,將目標股價下調至52美元
Benzinga ·  2023/11/03 12:49

Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $52.

坎託·菲茨傑拉德分析師克里斯汀·克魯斯卡維持Celldex Therapeutics(納斯達克股票代碼:CLDX)增持,並將目標股價從54美元下調至52美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論